Masimo (NASDAQ:MASI) said pre-market Friday that a new study showed that continuous and non-invasive hemoglobin monitoring using its SpHb may reduce excessive intraoperative red blood cell transfusion. Researchers compared 94 patients who had noninvasine hemoglobin measurements to a control group of 277 patients who did not. The results demonstrated a “significantly lower mean RBC transfusion volume per 1 g of blood loss” in the SpHb group versus the control group. Authors concluded that “SpHb measurements are associated with reducing excessive intraoperative RBC transfusion.” Masimo chief scientific officer Steven Barker said, “SpHb may be used to help clinicians make informed transfusion decisions during different types of surgery.”
The stock decreased 1.87% or $1.09 during the last trading session, hitting $57.31. About 216,208 shares traded hands. Masimo Corporation (NASDAQ:MASI) has risen 66.29% since February 8, 2016 and is uptrending. It has outperformed by 49.80% the S&P500.
Masimo Corporation is a medical technology firm that develops, makes and markets non-invasive patient monitoring products. The company has a market cap of $2.87 billion. The Company’s business is measure-through-motion and low-perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology pulse oximetry. It has a 29.92 P/E ratio. The Company’s product offerings include monitoring blood constituents with an optical signature, optical organ oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring and exhaled gas monitoring.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.